Results 121 to 130 of about 75,323 (218)

Adjuvant capecitabine in women with triple-negative breast cancer with residual disease after carboplatin-containing neoadjuvant chemotherapy. [PDF]

Breast Cancer Res Treat
Tavares GM, Ramalho SOB, da Silva LR, Telles GD, de Paiva Silva GR, Torresan RZ, Derchain SFM.   +6 more
europepmc   +1 more source

Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer. [PDF]

Breast Cancer Res Treat
Chiddarwar T, Blaes A, Kuntz K.
europepmc   +1 more source

Clinical Validation of Digital PCR-Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results. [PDF]

Clin Cancer Res
Roseshter T, Klemantovich A, Lafleur J, Lan C, Cavallone L, Bozek K, Guay J, Elebute O, Jenna S, Ouellette R, McNamara S, Boileau JF, Pelmus M, Brackstone M, Pezo R, Ng T, Aguilar-Mahecha A, Basik M.   +17 more
europepmc   +1 more source

AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012 [PDF]

, 2011
Harbeck, Nadia, Scharl, Anton, Thomssen, Christoph   +2 more
core   +2 more sources

Cost-effectiveness of switching to S-1 after fluoropyrimidine-induced hand-foot syndrome or cardiovascular toxicity in the treatment of metastatic colorectal cancer. [PDF]

ESMO Open
van Eekelen R, Punt CJA, Kwakman JJM, Coupé VMH.   +3 more
europepmc   +1 more source

Phase-Tuning of Ru Nanostructures in Ru/ZrO₂ Catalysts for Controlling Radical and Nonradical Pathways of Peroxymonosulfate-Based Oxidation and Defluorination of a Fluorinated Anticancer Drug. [PDF]

ACS Appl Mater Interfaces
Park J, Bae S, Choi Y, Choe JK.
europepmc   +1 more source

Capecitabine Dosage as an Independent Prognostic Factor for the Development of Hand-Foot Syndrome: A Competing Risk Analysis. [PDF]

Drug Healthc Patient Saf
Chantharakhit C, Patumanond J, Phinyo P, Chai-Adisaksopha C.   +3 more
europepmc   +1 more source

A Pharmacogenomic Basis for Tolerance of 5-Fluorouracil Following Early, Severe Toxicity from Capecitabine in a CDA Ultrarapid Metabolizer Colon Cancer Patient: A Case Report. [PDF]

Cancer Manag Res
Mazhindu TA, Chikwambi Z, Matsikidze E, Grimes KV, Borok MZ, Ndlovu N, Masimirembwa C, Consortium for Genomics and Therapeutics in Africa.   +7 more
europepmc   +1 more source

Impact of Thiazides and Fluoropyrimidines Interaction on Myelotoxicity and Other Adverse Events in Real-World Practice: A Retrospective Cohort Study. [PDF]

Cancer Med
Ronda-Roca G, Porcel-Maleno J, Lobo-Palomar M, Centeno-Soto G, Ruiz-Casado A, Ruiz-Antorán B.   +5 more
europepmc   +1 more source

TBKBP1 induces capecitabine resistance through negative regulation of type I interferon pathway in triple-negative breast cancer. [PDF]

Oncogene
Wu WY, Yang YS, Andriani L, Xie YF, Di GH, Shao ZM, Li JJ.   +6 more
europepmc   +1 more source